1. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Issue 8 (August 2019) Authors: Davids, Matthew S; Brander, Danielle M; Kim, Haesook T; Tyekucheva, Svitlana; Bsat, Jad; Savell, Alexandra; Hellman, Jeffrey M; Bazemore, Josie; Francoeur, Karen; Alencar, Alvaro; Shune, Leyla; Omaira, Mohammad; Jacobson, Caron A; Armand, Philippe; Ng, Samuel; Crombie, Jennifer; LaCasce, Ann S; A... Journal: Lancet Issue: Volume 6:Issue 8(2019) Page Start: e419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia. Issue 10 (October 2022) Authors: Soumerai, Jacob D; Takvorian, Ronald W; Sohani, Aliyah R; Abramson, Jeremy S; Ferry, Judith A Journal: Lancet Issue: Volume 9:Issue 10(2022) Page Start: e796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗